Article
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
Lung cancer (Amsterdam, Netherlands) - 1 Apr 2021
Cheng Ying, Mok Tony S, Zhou Xiangdong, Lu Shun, Zhou Qing, Zhou Jianying, Du Yingying, Yu Ping, Liu Xiaoqing, Hu Chengping, Lu You, Zhang Yiping, Lee Ki Hyeong, Nakagawa Kazuhiko, Linke Rolf, Wong Chew Hooi, Tang Yiyun, Zhu Fanfan, Wilner Keith D, Wu Yi-Long
Abstract excerpt
OBJECTIVES: To compare efficacy and safety of dacomitinib versus gefitinib as first-line therapy for EGFR mutation-positive advanced NSCLC in Asian patients enrolled in the ongoing ARCHER 1050 trial. MATERIALS AND METHODS: In this ongoing, randomized, open-label, phase 3 trial (NCT01774721), eligible patients with newly diagnosed advanced EGFR mutation-positive NSCLC were randomized (1:1) to receive oral...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.